VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--Variational AI, the company behind Enki™, an advanced foundation model for small molecule drug discovery, today ...
Merck & Co. is taking a look at a generative AI platform. As an early user of Variational AI’s technology, the Big Pharma will assess the ability of the platform to generate novel small molecules that ...
Merck & Co. has doubled down on its partnership with Variational AI, striking a deal worth up to $349 million to collaborate on small molecule candidates against two targets. Variational disclosed a ...
Variational AI, a Vancouver-based generative artificial intelligence (AI) drug discovery startup, is solving this problem by shifting from screening to generating. At the heart of its technology is ...
Merck & Co. has partnered with Variational AI to explore using artificial intelligence in drug discovery. Variational AI CEO Handol Kim says Merck will test Variational’s Enki platform in finding new ...
Merck & Co. Inc., (NYSE:MRK) is one of the best conservative stocks to buy now. On September 23, the company confirmed a strategic collaboration with Variational AI to leverage its Enki Platform in ...
Strategic Funding Led by Nimbus Synergies, Backed by Merck GHI, to Accelerate AI-Powered Collaborations VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback